Scientists at the Icahn School of Medicine at Mount Sinai have pioneered a groundbreaking immunotherapy aimed at addressing the challenges of metastatic cancer. Instead of directly attacking cancer cells, this novel approach focuses on tumor-associated macrophages (TAMs), the immune cells that protect tumors and maintain an immunosuppressive tumor microenvironment (TME). This strategy, likened to the tactics of a Trojan horse, seeks to disarm the defenses surrounding tumors, potentially revolutionizing treatment for advanced solid tumors.
Targeting the Tumor Microenvironment
The research team developed CAR T cells that produce interleukin-12 (IL-12) and specifically target TAMs. By disarming these macrophages, the CAR T cells can effectively open the gates for the immune system to infiltrate the tumor and eliminate cancerous cells. In rigorous preclinical studies involving aggressive models of metastatic ovarian and lung cancer, this therapy significantly improved survival rates, highlighting its potential as a viable treatment for advanced solid tumors.
Brian Brown, PhD, director of the Icahn Genomics Institute, emphasized the significance of this work, stating that targeting tumor macrophages presents a new avenue to combat cancers that are resistant to existing immunotherapeutic strategies. The findings were published in Cancer Cell, where the authors proposed that IL-12-producing, myeloid-directed CAR T cells could remodel the TME and enhance anti-tumor immunity.
Overcoming Immunosuppression
Metastatic cancers, particularly lung and ovarian cancers, account for a substantial number of cancer-related fatalities. Their treatment has proven challenging due to the tumors’ ability to suppress immune responses within the TME. This creates a protective barrier that enables cancer cells to thrive. The authors noted that even CAR T cells designed to target cancer cell-specific antigens struggle to overcome this immunosuppressive environment established by TAMs.
Healthy macrophages generally act as defenders against infections and aid in tissue repair. In contrast, within tumors, they become reprogrammed to assist cancer cells by inhibiting immune responses. Jaime Mateus-Tique, PhD, explained that tumors are essentially a fortress, surrounded by cells that shield them. The innovative strategy aims to transform these guards into allies, allowing for a more effective immune response against the cancer.
Engineering Anti-TAM CAR T Cells
The researchers engineered CAR T cells to specifically target TAMs by recognizing unique markers such as FOLR2 and TREM2, which are not commonly found on other cells. These engineered CAR T cells were further enhanced to produce IL-12, a powerful immune-activating molecule that stimulates the activity of killer T cells.
When applied to mouse models with metastatic lung and ovarian cancers, the IL-12-armored anti-TAM CAR T cells yielded remarkable outcomes. Mice treated with this therapy showed significantly extended survival rates, with several subjects achieving complete remission. These results underscore the potential of this innovative approach in the field of cancer therapy.
Analyzing Tumor Dynamics
To gain insights into the tumor dynamics following treatment, the researchers employed advanced spatial genomics techniques. These analyses revealed that the therapy effectively reshaped the tumor environment by depleting immune-suppressing cells and recruiting immune cells capable of attacking cancer. The data indicated that the IL-12 armored anti-TAM CAR T cells promoted tumor clearance, facilitating a robust T cell response against cancer cells.
This development introduces an antigen-independent therapy, which could be applicable to a variety of cancers, even those traditionally resistant to immunotherapy. The successful treatment of both lung and ovarian cancers suggests broad applicability for this method.
Transforming Macrophages into Allies
Brown highlighted the prevalence of macrophages in various tumor types, often outnumbering the cancer cells themselves. The findings illustrate an exciting potential to convert these cells from protecting the tumor to actively participating in its destruction. The research team is enthusiastic about the implications of this therapy, noting that it could reset the TME to a more immunostimulatory state, thereby promoting anti-tumor immunity and enhancing cancer clearance.
Future Directions and Human Studies
While the results are promising, the researchers caution that human clinical trials are essential to assess the safety and efficacy of this approach in patients. The findings should be viewed as a foundational proof of concept rather than a definitive cure. Plans are underway to refine the therapy further, particularly focusing on the precise control of IL-12 release within tumors in mouse models. The ultimate goal is to ensure maximum therapeutic effectiveness while prioritizing safety as the research progresses toward potential human testing.
Takeaways
- The new CAR T cell therapy targets tumor-associated macrophages rather than cancer cells, aiming to remodel the tumor microenvironment.
- Engineered CAR T cells producing IL-12 significantly improve survival in mouse models of metastatic lung and ovarian cancer.
-
This approach may lead to antigen-independent therapies that could treat various cancer types.
In conclusion, this innovative immunotherapy represents a significant step forward in cancer treatment. By transforming the role of macrophages from protectors of tumors to allies in their destruction, this strategy could pave the way for more effective treatments against solid tumors. As research progresses, the hope is to translate these findings into successful clinical applications that will benefit patients battling advanced-stage cancers.
Read more → www.genengnews.com